专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023042851A1 MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE 审中-公开
公开(公告)号：WO2023042851A1
公开(公告)日：2023-03-23
申请号：PCT/JP2022/034383
申请日：2022-09-14
申请人： SANTEN PHARMACEUTICAL CO., LTD. , BOEHRINGER INGELHEIM INTERNATIONAL GMBH
发明人： OKI, Kenji , NAGANO, Takashi , ASANO, Nagayoshi , FUJISAWA, Koushi
IPC分类号： A61K31/538 , A61P27/02 , A61P43/00
摘要： A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates to a medicament for preventing and/or treating dry eye, comprising olodaterol or a salt thereof as an active ingredient.

2. 发明申请

WO2017204298A1 USE OF SIROLIMUS TO TREAT EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH PERSISTENT EDEMA 审中-公开
标题翻译：利用SIROLIMUS治疗与持续性EDEMA相关的年龄相关性黄斑变性
公开(公告)号：WO2017204298A1
公开(公告)日：2017-11-30
申请号：PCT/JP2017/019551
申请日：2017-05-25
申请人： SANTEN PHARMACEUTICAL CO., LTD.
发明人： MATURI, Raj K.
IPC分类号： A61K31/436 , A61P7/10 , A61P27/02
摘要： This invention relates to a method for treatment of persistent edema in patients with exudative age-related macular degeneration. In particular, the present invention relates to treatment of wet age-related macular degeneration with intravitreal sirolimus in subjects that had an inadequate response to prior treatment with an intravitreal anti-vascular endothelial growth factor agent.
摘要翻译：本发明涉及一种治疗渗出性年龄相关性黄斑变性患者持久性水肿的方法。具体而言，本发明涉及在玻璃体内抗血管内皮生长因子剂对事先治疗具有不足响应的受试者中用玻璃体内西罗莫司治疗湿性年龄相关性黄斑变性。

3. 发明申请

WO2011001634A1 METHOD FOR IMPROVING BIOAVAILABILITY OF LATANOPROST 审中-公开
标题翻译：改善LATANOPROST生物利用度的方法
公开(公告)号：WO2011001634A1
公开(公告)日：2011-01-06
申请号：PCT/JP2010/004179
申请日：2010-06-23
申请人： SANTEN PHARMACEUTICAL CO., LTD. , REUNAMAKI, Timo , TERVO, Paula , LOKKILA, Jukka , PELLINEN, Pertti , ALAJUUMA, Paivi , OKSALA, Olli
发明人： REUNAMAKI, Timo , TERVO, Paula , LOKKILA, Jukka , PELLINEN, Pertti , ALAJUUMA, Paivi , OKSALA, Olli
IPC分类号： A61K31/5575 , A61J1/05 , A61K9/08 , A61K47/18 , A61K47/32 , A61K47/38 , A61P27/06
CPC分类号： A61K9/0048 , A61K47/18
摘要： The present invention relates to a method for improving ocular bioavailability of latanoprost by adding an organic amine to an aqueous eye drop composition containing latanoprost. The invention further relates to an aqueous eye drop composition in which a better ocular bioavailability of latanoprost is achieved by adding an organic amine, and to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment.
摘要翻译：本发明涉及通过向含有拉坦前列素的含水滴眼液组合物中加入有机胺来改善拉坦前列素的眼部生物利用度的方法。本发明还涉及一种水性滴眼剂组合物，其中拉坦前列素的更好的眼部生物利用度通过加入有机胺来实现，以及通过将所述组合物施用于需要这种治疗的受试者来治疗高眼压症和青光眼的方法。

4. 发明申请

WO1997049419A1 OPHTHALMIC DRUG COMPOSITIONS 审中-公开
标题翻译： OPHTHALMIC药物组合物
公开(公告)号：WO1997049419A1
公开(公告)日：1997-12-31
申请号：PCT/JP1997002015
申请日：1997-06-11
申请人： SANTEN PHARMACEUTICAL CO., LTD. , NISHIDA, Teruo , NAKAMURA, Masatsugu , NAKATA, Katsuhiko
发明人： SANTEN PHARMACEUTICAL CO., LTD.
IPC分类号： A61K38/07
CPC分类号： C07K5/1016 , A61K9/0048 , A61K38/046 , A61K38/07 , C07K7/22 , Y10S514/912
摘要： The minimum activity-exhibiting site of substance P has now been found and the action of a compound consisting of the units constituting the minimum site on the ophthalmic region has been elucidated, on the basis of which the following ophthalmic drug compositions containing the above compound as the active ingredient are provided: an ophthalmic drug composition (particularly corneal disease remedy) containing as the active ingredient Phe-Gly-Leu-Met-NH2 or a pharmaceutically acceptable salt thereof; and a corneal disease remedy (particularly elongation accelerator for corneal epithelium) containing as the active ingredients Phe-Gly-Leu-Met-NH2 or a pharmaceutically acceptable salt thereof and insulin-like growth factor-I. These preparations preferably take the dosage form of eye drops.
摘要翻译：已经发现物质P的最低活性表现位点，并且已经阐明了由构成眼部区域的最小部位的单元组成的化合物的作用，基于此，含有上述化合物的下列眼用药物组合物提供活性成分：含有作为活性成分Phe-Gly-Leu-Met-NH 2或其药学上可接受的盐的眼用药物组合物（特别是角膜疾病治疗剂）以及作为活性成分Phe-Gly-Leu-Met-NH 2或其药学上可接受的盐和胰岛素样生长因子-I的角膜疾病治疗（特别是角膜上皮的延伸促进剂）。这些制剂优选采用滴眼剂的剂型。

5. 发明申请

WO1996014293A1 NOVEL 1,3-DIALKYLUREA DERIVATIVE HAVING HYDROXYL GROUP 审中-公开
标题翻译：具有羟基的新型1,3-二氨基脲衍生物
公开(公告)号：WO1996014293A1
公开(公告)日：1996-05-17
申请号：PCT/JP1995002236
申请日：1995-11-01
申请人： SANTEN PHARMACEUTICAL CO., LTD. , KAWASHIMA, Yoichi , FUJIMURA, Ken-ichi , SUHARA, Hiroshi , MIYAWAKI, Nobuaki , FUJITA, Yuko
发明人： SANTEN PHARMACEUTICAL CO., LTD.
IPC分类号： C07C275/10
CPC分类号： C07C275/24 , C07C2601/14
摘要： A compound represented by general formula (I) and salts thereof, wherein R and R represent carboxyl optionally converted into an ester, amide or hydroxamate group; R represents lower alkyl or phenyl lower alkyl; and R represents hydrogen, lower alkyl, amino lower alkyl, lower alkylamino lower alkyl, hydroxy lower alkyl, mercapto lower alkyl, carboxy lower alkyl, lower alkoxycarbonyl lower alkyl, imidazolyl lower alkyl, indolyl lower alkyl, optionally substituted phenyl, optionally substituted phenyl lower alkyl, optionally substituted naphthyl or optionally substituted naphthyl lower alkyl. The compound has an inhibitory effect on endopeptidase 24.11 and being useful as a remedy for cardiovascular diseases such as cardiac insufficiency and hypertension, kidney diseases such as renal insufficiency, gastrointestinal disorders such as diarrhea and gastric hyperacidity, endocrine/metabolic diseases such as obesity, and autoimmune diseases such as rheumatism, and as an analgesic agent for muscular pain, hemicrania, etc.
摘要翻译：由通式（I）表示的化合物及其盐，其中R 1和R 4表示任选转化为酯，酰胺或异羟肟基的羧基; R 2表示低级烷基或苯基低级烷基; R 3表示氢，低级烷基，氨基低级烷基，低级烷基氨基低级烷基，羟基低级烷基，巯基低级烷基，羧基低级烷基，低级烷氧基羰基低级烷基，咪唑基低级烷基，吲哚基低级烷基，任意取代的苯基，取代的苯基低级烷基，任选取代的萘基或任选取代的萘基低级烷基。该化合物对内肽酶24.11具有抑制作用，可用作心血管疾病如心功能不全和高血压，肾脏疾病如肾功能不全，胃肠疾病如腹泻和胃酸过多，内分泌/代谢疾病如肥胖症的补救措施，以及自身免疫性疾病如风湿病，以及作为肌肉疼痛，血红素等的镇痛剂。

6. 发明申请

WO1995013269A1 1,4-BENZOTHIAZINE DERIVATIVE 审中-公开
公开(公告)号：WO1995013269A1
公开(公告)日：1995-05-18
申请号：PCT/JP1994001907
申请日：1994-11-10
申请人： SANTEN PHARMACEUTICAL CO., LTD. , KAWASHIMA, Yoichi , OTA, Atsutoshi , MIBU, Hiroyuki , MATSUBAYASHI, Kenichiro
发明人： SANTEN PHARMACEUTICAL CO., LTD.
IPC分类号： C07D279/12
CPC分类号： C07D279/16
摘要： A compound represented by general formula (I) or a salt thereof and an intermediate for synthesizing the same wherein R represents optionally protected hydroxy; R represents lower alkyl; R represents hydrogen, lower alkyl, optionally protected hydroxy or lower alkoxy, wherein the lower alkyl group may be substituted by optionally protected hydroxy, amino or lower alkylamino; R represents carboxyl which may be in the form of an ester or amide; A represents alkylene; and B represents -CH2- or >C=S. This compound has the activities of stabilizing proteins and inhibiting lipid peroxide formation, and is promising as an excellent cataract remedy.
摘要翻译：由通式（I）表示的化合物或其盐和用于合成其的中间体，其中R 1表示任选保护的羟基; R 2表示低级烷基; R 3表示氢，低级烷基，任选保护的羟基或低级烷氧基，其中低级烷基可被任选被保护的羟基，氨基或低级烷基氨基取代; R 4表示可以是酯或酰胺形式的羧基; A表示亚烷基; B表示-CH 2 - 或> C = S。该化合物具有稳定蛋白质和抑制脂质过氧化物形成的活性，并且作为优异的白内障治疗是有希望的。

7. 发明申请

WO1989000044A1 ARTIFICIAL LACRIMA 审中-公开
标题翻译：人造LACRIMA
公开(公告)号：WO1989000044A1
公开(公告)日：1989-01-12
申请号：PCT/JP1988000674
申请日：1988-07-06
申请人： SANTEN PHARMACEUTICAL CO., LTD. , IWAO, Jun-ichi , ISO, Tadashi , UEMURA, Osamu , KAWASHIMA, Yo-ichi
发明人： SANTEN PHARMACEUTICAL CO., LTD.
IPC分类号： A61K09/08
CPC分类号： A61K31/715 , A61K9/0048
摘要： An artificial lacrima containing sodium hyaluronate and having a pH of 5.5 to 8.0 and an osmotic pressure ratio (to physiological saline) of 0.85 to 1.55, and a drug for treating corneal xerosis which contains sodium hyaluronate as a major component are disclosed.

8. 发明申请

WO1983000865A1 BENZOTHIAZOLINE COMPOUNDS 审中-公开
标题翻译：苯并噻唑化合物
公开(公告)号：WO1983000865A1
公开(公告)日：1983-03-17
申请号：PCT/JP1982000363
申请日：1982-09-10
申请人： SANTEN PHARMACEUTICAL CO., LTD. , IWAO, Jun-ichi , OYA, Masayuki , ISO, Tadashi
发明人： SANTEN PHARMACEUTICAL CO., LTD.
IPC分类号： C07D277/66
CPC分类号： C07D277/66
摘要： Benzothiazoline derivatives represented by the general formula (I): wherein R represents a lower alkanoyl group, R represents one or more groups selected from among a hydrogen atom, a lower alkyl group, a lower alkoxy group, a hydroxy group, a halogen atom, a nitro group, a halogen-substituted lower alkyl group, and a sulfamoyl group, R represents or -COR , R and R each represents a hydrogen atom, a lower alkyl group, a cyclohexyl group or a substituted lower alkyl group, R represents a hydrogen atom, an alkyl group, a substituted alkyl group, an alkanoyl group, a substituted alkanoyl group, an alkenoyl group, a substituted alkenoyl group or a furylcarbonyl group, R represents a hydrogen atom, a hydroxy group, a phenyl-lower alkyl group or a benzoyl group, R represents a hydroxy group, a lower alkoxy group, represents a straight or branched alkylene group containing 1 to 6 carbon atoms, m represents 0 or 1, n represents 0 or 1, and p represents 4 or 5, and salts thereof, useful for treating cardiovascular diseases, and a process for their preparation.
摘要翻译：由通式（I）表示的苯并噻唑啉衍生物：其中R 1表示低级烷酰基，R 2表示选自氢原子，低级烷基，低级烷氧基中的一个或多个基团，羟基，卤素原子，硝基，卤素取代的低级烷基和氨磺酰基，R 3表示“或”或“-COR”，R 4和R 5均为H. 各自表示氢原子，低级烷基，环己基或取代的低级烷基，R 6表示氢原子，烷基，取代的烷基，烷酰基，取代的烷酰基，烯酰基基团，取代的烯酰基或呋喃基羰基，R 7表示氢原子，羟基，苯基 - 低级烷基或苯甲酰基，R 8表示羟基，低级烷氧基， IMAGE>表示含有1至6个碳原子的直链或支链亚烷基，m表示0或1，n表示0或1，p 呈现4或5及其盐，可用于治疗心血管疾病，及其制备方法。

9. 发明申请

WO2019133735A1 DEPOT FORMULATIONS 审中-公开
公开(公告)号：WO2019133735A1
公开(公告)日：2019-07-04
申请号：PCT/US2018/067724
申请日：2018-12-27
申请人： DURECT CORPORATION , SANTEN PHARMACEUTICAL CO., LTD.
发明人： TAMRAZ, Wilma , SU, Huey-Ching Lin , LIN, WeiQi , YAMADA, Kazuhito , MATSUMOTO, Naoki , MUDUMBA, Sreenivasu , OKABE, Komei
IPC分类号： A61K47/10 , A61K47/14 , A61K9/00
摘要： Pharmaceutical compositions comprising an active pharmaceutical ingredient, a high viscosity liquid carrier material, a hydrophobic solvent, and a hydrophilic solvent are disclosed. Also disclosed are methods of manufacturing and using the compositions. The compositions are suitable for use, e.g., as depot formulations.

10. 发明申请

WO2018174149A1 AGENT FOR PREVENTING MYOPIA, TREATING MYOPIA, AND/OR PREVENTING MYOPIA PROGRESSION COMPRISING TIOTROPIUM AS ACTIVE INGREDIENT 审中-公开
公开(公告)号：WO2018174149A1
公开(公告)日：2018-09-27
申请号：PCT/JP2018/011361
申请日：2018-03-22
申请人： SINGAPORE HEALTH SERVICES PTE LTD , SANTEN PHARMACEUTICAL CO., LTD.
发明人： TAN, Donald , BEUERMAN, Roger , SAW, Seang-Mei , UPADHYAY, Aradhana , KATO, Masatomo , INABA, Takaaki
IPC分类号： A61K31/439 , A61P27/10
摘要： The present invention relates to an agent for preventing myopia, treating myopia, and/or preventing myopia progression, comprising tiotropium as an active ingredient.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式